Amylyx Pharmaceuticals, Inc.
AMLX
주식 순위
#4625
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
주가
$26.28
마지막 동기화: 2026-10-16
시가총액
$3.30B
변동 (1일)
-4.95%
변동 (1년)
75.79%
국가
US
거래 Amylyx Pharmaceuticals, Inc. (AMLX)
카테고리
Healthcare
Amylyx Pharmaceuticals, Inc. (AMLX)의 EPS
June 2026 기준 EPS TTM: $-1.41
Amylyx Pharmaceuticals, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 $-1.41입니다. 2023년 말에는 회사의 EPS가 $0.73였으며, 이는 2022년의 EPS $-2.98와 증가입니다.
Amylyx Pharmaceuticals, Inc.의 EPS 기록 (2019 ~ 2026)
매년 말의 EPS
| 연도 | EPS | 변화 |
|---|---|---|
| 2026 (TTM) | $-1.41 | -68.17% |
| 2024 | $-4.43 | -706.85% |
| 2023 | $0.73 | -124.50% |
| 2022 | $-2.98 | 96.05% |
| 2021 | $-1.52 | 92.41% |
| 2020 | $-0.79 | 203.85% |
| 2019 | $-0.26 | 0.00% |
유사 기업 또는 경쟁사의 EPS
| 회사 | EPS | EPS 차이 | 국가 |
|---|---|---|---|
| $17.32 | -1,328.37% |
US
|
|
| $-7.98 | 465.96% |
US
|
|
| $-5.29 | 275.18% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,067.38% |
NL
|
